ArticleLeukemia2006
BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
Article in Leukemia, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- The GF-NEO discovery platform unveils a [KQE][DG] sequence motif within fusion neoantigens in pediatric cancer.iScience · 2026Article
- The Immunoproteasome Is Expressed but Dispensable for a Leukemia Infected Cell Vaccine.Vaccines · 2025Article
- Article
- The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.Nature communications · 2022Article
- In vitro proteasome processing of neo-splicetopes does not predict their presentation in vivo.eLife · 2021Article
- TCR Redirected T Cells for Cancer Treatment: Achievements, Hurdles, and Goals.Frontiers in immunology · 2020Review
- Antigen Targets for the Development of Immunotherapies in Leukemia.International journal of molecular sciences · 2019Review
- Cytokine Syntheses by T-Cell Subsets From Chronic Myeloid Leukemia Patients: Relationship Between Pre-Treatment Levels and Response to Imatinib Therapy.Journal of hematology · 2018Article
- Introduction of neutralizing immunogenicity index to the rational design of MERS coronavirus subunit vaccines.Nature communications · 2016Article
- Immunology and immunotherapy of chronic myeloid leukemia.Current hematologic malignancy reports · 2014Review
- The role of peptide and DNA vaccines in myeloid leukemia immunotherapy.Cancer cell international · 2013Article
- Sequence and expression of the chicken membrane-associated phospholipases A1 alpha (LIPH) and beta (LIPI).Molecular biology reports · 2012Article
- Vaccines against human carcinomas: strategies to improve antitumor immune responses.Journal of biomedicine & biotechnology · 2010Review
- Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?Cancer immunology, immunotherapy : CII · 2009Review
- BCR/ABL-specific CD8+ T cells can be detected from CML patients, but are only expanded from healthy donors.Cancer immunology, immunotherapy : CII · 2009Article
- Immunotherapy in acute leukemia.Seminars in hematology · 2009Review
- Review
- Identification of T-cell epitopes for cancer immunotherapy.Leukemia · 2007Review
- Translational mini-review series on vaccines: Peptide vaccines for myeloid leukaemias.Clinical and experimental immunology · 2007Review
- T cell receptor mimic antibodies for cancer therapy.OncoimmunologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For immunotherapy of residual disease in patients with Philadelphia-positive leukemias, the BCR-ABL fusion regions are attractive disease-specific T-cell targets. We analyzed these regions for the prevalence of cytotoxic T lymphocyte (CTL) epitopes by an advanced reverse immunology procedure. Seventeen novel BCR-ABL fusion peptides were identified to bind efficiently to the human lymphocyte antigen (HLA)-A68, HLA-B51, HLA-B61 or HLA-Cw4 HLA class I molecules. Comprehensive enzymatic digestion analysis showed that 10 out of the 28 HLA class I binding fusion peptides were efficiently excised after their C-terminus by the proteasome, which is an essential requirement for efficient cell surface expression. Therefore, these peptides are prime vaccine candidates. The other peptides either completely lacked C-terminal liberation or were only inefficiently excised by the proteasome, rendering them inappropriate or less suitable for inclusion in a vaccine. CTL raised against the properly processed HLA-B61 epitope AEALQRPVA from the BCR-ABL e1a2 fusion region, expressed in acute lymphoblastic leukemia (ALL), specifically recognized ALL tumor cells, proving cell surface presentation of this epitope, its applicability for immunotherapy and underlining the accuracy of our epitope identification strategy. Our study provides a reliable basis for the selection of optimal peptides to be included in immunotherapeutic BCR-ABL vaccines against leukemia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.